Global Microbiome Therapeutics Market 2021

January 2022 | 18 pages | ID: GFB6068FE8F6EN
StrategyHelix Inc

Abstracts

The microbiome is the natural bacterial colonisation of the body - including skin, gut and stomach. The human microbiome refers to the spectrum of microbes (microbiota) that colonize humans. Microbiome therapies are currently focused on the prevention of C. difficile recurrence. This bacterium is often contracted in hospitals following antibiotic administration or a period of immunosuppression. The global microbiome therapeutics market is poised to grow by US$ 918 million from 2021 to 2027, registering a CAGR of 32.5% during the forecast period, according to StrategyHelix. Significant external funding for executing research and therapeutic innovation, increasing adoption of inorganic growth strategies in the market, growing demand for novel therapies to address the unmet needs of many diseases are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for microbiome therapeutics. The global microbiome therapeutics market is segmented on the basis of target therapy area, and region. By target therapy area, the global microbiome therapeutics market has been segmented into gastrointestinal diseases, infections, others. In 2020, the gastrointestinal diseases segment made up the largest share of revenue generated by the microbiome therapeutics market. In terms of geography, the global microbiome therapeutics market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global microbiome therapeutics market is highly competitive. As of 2020, the major players in the global microbiome therapeutics market were 4D Pharma plc, AOBiome Therapeutics Inc., Assembly Biosciences Inc., Eligo Bioscience S.A.S, Finch Therapeutics Group Inc., MaaT Pharma SA, Quorum Innovations LLC, Rebiotix Inc. (Ferring Pharmaceuticals Group), Seres Therapeutics Inc., Synthetic Biologics, Vedanta Biosciences Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the microbiome therapeutics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope
Target therapy area: gastrointestinal diseases, infections, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global microbiome therapeutics market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. MICROBIOME THERAPEUTICS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY TARGET THERAPY AREA

Gastrointestinal diseases
Infections
Others

PART 4. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 5. KEY COMPANIES

4D PHARMA PLC

AOBiome Therapeutics, Inc.
Assembly Biosciences, Inc.
Eligo Bioscience S.A.S
Finch Therapeutics Group, Inc.
MaaT Pharma SA
Quorum Innovations, LLC
Rebiotix, Inc. (Ferring Pharmaceuticals Group)
Seres Therapeutics, Inc.
Synthetic Biologics
Vedanta Biosciences, Inc.
About StrategyHelix
Disclaimer